Oct 22, 2026 07:30AM
Oct 22, 2026 07:30AM
Aug 12, 2026 07:00AM
Jul 15, 2026 07:31AM
Jul 15, 2026 07:30AM
Jul 7, 2026 07:30AM
Jun 17, 2026 12:30PM JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform
Jun 16, 2026 07:32AM
Jun 16, 2026 07:30AM
May 12, 2026 07:00AM
Mar 26, 2026 07:00AM
Mar 17, 2026 08:00AM
Mar 17, 2026 08:00AM
Mar 3, 2026 08:00AM Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
Mar 3, 2026 08:00AM
Jan 27, 2026 05:59AM
Dec 2, 2025 08:00AM
Dec 2, 2025 08:00AM
Nov 18, 2025 08:00AM
Nov 18, 2025 08:00AM
Nov 17, 2025 08:00AM Acumen Pharmaceuticals doses first patient in sabirnetug extension study
Nov 17, 2025 08:00AM
Nov 12, 2025 07:00AM
Aug 12, 2025 07:00AM
Jul 28, 2025 08:00AM
Jul 28, 2025 08:00AM
Jul 15, 2025 07:01AM
Jul 15, 2025 07:00AM Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease
Jul 10, 2025 08:00AM
May 13, 2025 07:00AM
Apr 2, 2025 07:00AM
Apr 2, 2025 07:00AM
Apr 1, 2025 07:00AM
Mar 27, 2025 07:00AM
Mar 26, 2025 08:05AM Acumen Pharmaceuticals (ABOS) Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
Mar 26, 2025 08:00AM
Mar 19, 2025 08:00AM
Mar 19, 2025 08:00AM
Mar 12, 2025 08:00AM
Jan 9, 2025 08:00AM
Nov 12, 2024 07:00AM
Nov 6, 2024 08:01AM Acumen Pharmaceuticals, Inc (ABOS) Appoints Amy Schacterle as Chief Regulatory Officer & Head of Quality
Nov 6, 2024 08:00AM
Nov 6, 2024 08:00AM
Oct 31, 2024 08:05AM
Oct 23, 2024 08:02AM
Oct 23, 2024 08:00AM
Sep 26, 2024 08:02AM
Sep 26, 2024 08:00AM Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
Aug 13, 2024 07:00AM

335,195 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All